Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

PROSTATE CANCER

Prostate cancer screening: a new way forward or another false start?

Serum PSA testing can identify men with clinically significant prostate cancer but exposes many more men to the diagnosis of indolent tumours. Benafif and colleagues have published the results of the BARCODE1 pilot study, in which they propose using germline single-nucleotide polymorphisms to identify men with a genetic risk of developing prostate cancer. Based on their preliminary findings, changing the current prostate cancer screening paradigm will be a challenge.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Catalona, W. J. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324, 1156–1161 (1991).

    CAS  Article  Google Scholar 

  2. 2.

    Lane, J. A. et al. Active monitoring, radical prostatectomy, or radiotherapy for localized prostate cancer: study design and diagnostic baseline results of the ProtecT randomized phase 3 trial. Lancet Oncol. 15, 1109–1118 (2014).

    Article  Google Scholar 

  3. 3.

    Nordström, T. et al. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur. Urol. 68, 139–146 (2015).

    Article  Google Scholar 

  4. 4.

    Grönberg, H. et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 16, 1667–1676 (2015).

    Article  Google Scholar 

  5. 5.

    Eklund, M. et al. MRI-targeted or standard biopsy in prostate cancer screening. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2100852 (2021).

    Article  PubMed  Google Scholar 

  6. 6.

    Schumacher, F. R. et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat. Genet. 50, 928–936 (2018).

    CAS  Article  Google Scholar 

  7. 7.

    Benafif, S. et al. The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. BJU Int. https://doi.org/10.1111/BJU.15535 (2021).

    Article  PubMed  Google Scholar 

  8. 8.

    Welch, H. G. & Albertsen, P. C. Reconsidering prostate cancer mortality – the future of PSA screening. N. Engl. J. Med. 382, 1557–1563 (2020).

    Article  Google Scholar 

  9. 9.

    Fenton, J. J. et al. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA 319, 1914–1931 (2018).

    Article  Google Scholar 

  10. 10.

    Kovac, E. et al. Association of baseline prostate-specific antigen level with long-term diagnosis of clinically significant prostate cancer among patients aged 55 to 60 years: a secondary analysis of a cohort in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. JAMA Netw. Open 3, e1919284 (2020).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Peter C. Albertsen.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Albertsen, P.C. Prostate cancer screening: a new way forward or another false start?. Nat Rev Urol 18, 579–580 (2021). https://doi.org/10.1038/s41585-021-00513-w

Download citation

Search

Quick links